Dianthus Therapeutics Inc (NASDAQ: DNTH) on Friday, plunged -5.00% from the previous trading day, before settling in for the closing price of $24.81. Within the past 52 weeks, DNTH’s price has moved between $13.36 and $32.27.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 40.14%. The company achieved an average annual earnings per share of -36.44%. With a float of $23.48 million, this company’s outstanding shares have now reached $32.18 million.
Dianthus Therapeutics Inc (DNTH) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Dianthus Therapeutics Inc is 27.05%, while institutional ownership is 102.60%.
Dianthus Therapeutics Inc (DNTH) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.74 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.6) by -0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -36.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -14.51% during the next five years compared to 40.14% growth over the previous five years of trading.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Trading Performance Indicators
Dianthus Therapeutics Inc (DNTH) is currently performing well based on its current performance indicators. A quick ratio of 13.12 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 156.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.25, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -3.65 in one year’s time.
Technical Analysis of Dianthus Therapeutics Inc (DNTH)
Looking closely at Dianthus Therapeutics Inc (NASDAQ: DNTH), its last 5-days average volume was 0.37 million, which is a jump from its year-to-date volume of 0.33 million. As of the previous 9 days, the stock’s Stochastic %D was 78.12%.
During the past 100 days, Dianthus Therapeutics Inc’s (DNTH) raw stochastic average was set at 84.72%, which indicates a significant increase from 71.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.54 in the past 14 days, which was higher than the 1.41 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.55, while its 200-day Moving Average is $21.11. However, in the short run, Dianthus Therapeutics Inc’s stock first resistance to watch stands at $24.92. Second resistance stands at $26.28. The third major resistance level sits at $27.33. If the price goes on to break the first support level at $22.51, it is likely to go to the next support level at $21.46. Should the price break the second support level, the third support level stands at $20.10.
Dianthus Therapeutics Inc (NASDAQ: DNTH) Key Stats
Market capitalization of the company is 758.68 million based on 32,188K outstanding shares. Right now, sales total 6,240 K and income totals -84,970 K. The company made 190 K in profit during its latest quarter, and -31,630 K in sales during its previous quarter.
